
    
      This is a first in human research study (Phase I clinical trial) to test the safety and
      effectiveness of a new radioactive PET imaging drug and biomarker [68Ga]-NOTA-hGZP. It is a
      multi-center, open label, non-randomized, single dose drug trial in metastatic melanoma or
      NSCLC participants.
    
  